BioWorld

June 26, 2007

View Archived Issues

GPC Draws $10M Up Front In Japanese Marketing Deal

One month away from an FDA panel review, GPC Biotech Inc.'s satraplatin for prostate cancer has become the subject of a $10 million license deal with Yakult Honsha Co. Ltd., for rights in Japan. (BioWorld Today) Read More

DPP-IV Inhibitor Data Abound As Januvia Competition Draws Near

Read More

Targeting Immunity, Not Invader, Key To Broad-Spectrum Antiviral

Read More

Argolyn Adds $16M In Series A For Peptide Drug Development

Read More

Other News To Note

Read More

Clinic Roundup

Read More